Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054028 · ClinicalTrials.gov registry record · Phase 1
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00054028: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00054028 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054028, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Suramin may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug.
Interventions
- DRUG paclitaxel
- OTHER pharmacological study
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2002-12 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054028
The ClinicalTrials.gov registry entry for NCT00054028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00054028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054028 about?
NCT00054028 is a clinical study titled "Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer". This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Suramin may increase the effectiveness of paclit...
What is the current status of trial NCT00054028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2002-12. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00054028?
The interventions under investigation include: paclitaxel (DRUG), pharmacological study (OTHER), suramin (DRUG).
Who is sponsoring clinical trial NCT00054028?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.